A Phase I, Open-Label Study to Investigate the Safety and Tolerability of AZD6244 (Selumetinib) When Given as a Monotherapy in Japanese Patients With Advanced Solid Malignancies, and When Given in Combination With Docetaxel as 2nd Line Therapy in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV)
Overview
- Phase
- Phase 1
- Intervention
- AZD6244
- Conditions
- Neoplasms,
- Sponsor
- AstraZeneca
- Enrollment
- 33
- Locations
- 1
- Primary Endpoint
- Cmax of Selumetinib During Oral Twice Daily Dose of Selumetinib
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
The objective of this study will be to investigate the safety and tolerability of AZD6244 given monotherapy or in combination with docetaxel as 2nd line therapy in Japanese patients with Advanced Solid Malignancies or Locally Advanced or Metastatic Non-Small Cell Lung Cancer. In addition, the pharmacokinetic profile of AZD6244 will be investigated. Following the combination regimen dose escalation phase (Part A) of the study additional patients may be enrolled to a dose expansion phase (Part B) to refine further the safety, tolerability, pharmacokinetics and biological activity of the combination in this patient population.
Detailed Description
The objective of the combination therapy part of this study will be to investigate the safety and tolerability of AZD6244 given in combination with docetaxel as 2nd line therapy in Japanese patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV). In addition, the pharmacokinetic profile of AZD6244 and docetaxel will be investigated. The objective of the monotherapy part of this study will be to investigate the safety and tolerability of AZD6244 given as a monotherapy in Japanese patients with advanced solid malignancies. In addition, the pharmacokinetic profile of monotherapy AZD6244 will be investigated.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients diagnosed with lung cancer who have not responded to prior therapy or have become worse.
- •Patients who have overall good general conditions.
- •Patients who have at least one lesion that can be accurately assessed by imaging.
- •Patients who have appropriate renal conditions confirmed by test results for taking part in the study.
- •Evidence of non-childbearing status for women of childbearing potential, or postmenopausal status.
Exclusion Criteria
- •Patients with brain metastases or spinal cord compression.
- •Patients with significant abnormal ECG findings.
- •Patients with evidence of severe or uncontrolled systemic disease.
- •The main organ functional test values for bone marrow, kidney, and liver, etc., do not meet the standards.
- •Patients with known hypersensitivity to docetaxel or products containing polysorbate
- •Only for monotherapy cohort eligibility criteria Patients with advanced solid malignancies refractory to standard treatment or for which no standard therapy exists irrespective of the stage and previous treatment.
- •Patients with histologically or cytologically confirmed advanced solid malignancies.
Arms & Interventions
Selumetinib (AZD6244) 25 mg
monotherapy
Intervention: AZD6244
Selumetinib (AZD6244) 50 mg
monotherapy
Intervention: AZD6244
Selumetinib (AZD6244) 75 mg
monotherapy
Intervention: AZD6244
Selumetinib (AZD6244) 75 mg + Doce
Combination
Intervention: AZD6244
Selumetinib (AZD6244) 25 mg + Doce
combination
Intervention: AZD6244
Outcomes
Primary Outcomes
Cmax of Selumetinib During Oral Twice Daily Dose of Selumetinib
Time Frame: Day 8: 0, 0.5, 1, 1.5, 2, 4, 8, 12 hours post-dose
Pharmacokinetic parameter (Cmax: maximum plasma concentration) of Selumetinib during oral twice daily dose of Selumetinib
AUC(0-12) of N-desmethyl Selumetinib During Oral Twice Daily Dose of Selumetinib
Time Frame: Day 8: 0, 0.5, 1, 1.5, 2, 4, 8, 12 hours post-dose
Pharmacokinetic parameter (AUC(0-12): area under the plasma concentration-time curve from zero to 12 hours post-dose) of N-desmethyl Selumetinib during oral twice daily dose of Selumetinib
Cmax of N-desmethyl Selumetinib During Oral Twice Daily Dose of Selumetinib
Time Frame: Day 8: 0, 0.5, 1, 1.5, 2, 4, 8, 12 hours post-dose
Pharmacokinetic parameter (Cmax: maximum plasma concentration) of N-desmethyl Selumetinib during oral twice daily dose of Selumetinib
Cmax of Selumetinib After Single Dose
Time Frame: Day 1: 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48, 72 hours post-dose
Pharmacokinetic parameter (Cmax: maximum plasma concentration) of Selumetinib following single oral dose of Selumetinib
Tmax of Selumetinib After Single Dose
Time Frame: Day 1: 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48, 72 hours post-dose
Pharmacokinetic parameter (tmax: time to reach the maximum plasma concentration) of Selumetinib following single oral dose of Selumetinib
AUC(0-12) of Selumetinib After Single Dose
Time Frame: Day 1: 0, 0.5, 1, 1.5, 2, 4, 8, 12 hours post-dose
Pharmacokinetic parameter (AUC(0-12): area under the plasma concentration-time curve from zero to 12 hours post-dosey) of Selumetinib following single oral dose of Selumetinib
Cmax of N-desmethyl Selumetinib After Single Dose
Time Frame: Day 1: 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48, 72 hours post-dose
Pharmacokinetic parameter (Cmax: maximum plasma concentration) of N-desmethyl Selumetinib following single oral dose of Selumetinib
Tmax of N-desmethyl Selumetinib After Single Dose
Time Frame: Day 1: 0, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48, 72 hours post-dose
Pharmacokinetic parameter (tmax: time to reach the maximum plasma concentration) of N-desmethyl Selumetinib following single oral dose of Selumetinib
AUC(0-12) of N-desmethyl Selumetinib After Single Dose
Time Frame: Day 1: 0, 0.5, 1, 1.5, 2, 4, 8, 12 hours post-dose
Pharmacokinetic parameter (AUC(0-12): area under the plasma concentration-time curve from zero to 12 hours post-dose) of N-desmethyl Selumetinib following single oral dose of Selumetinib
AUC(0-12) of Selumetinib During Oral Twice Daily Dose of Selumetinib
Time Frame: Day 8: 0, 0.5, 1, 1.5, 2, 4, 8, 12 hours post-dose
Pharmacokinetic parameter (AUC(0-12): area under the plasma concentration-time curve from zero to 12 hours post-dose) of Selumetinib during oral twice daily dose of Selumetinib
Tmax of N-desmethyl Selumetinib During Oral Twice Daily Dose of Selumetinib
Time Frame: Day 8: 0, 0.5, 1, 1.5, 2, 4, 8, 12 hours post-dose
Pharmacokinetic parameter (tmax: time to reach the maximum plasma concentration) of N-desmethyl Selumetinib during oral twice daily dose of Selumetinib
Tmax of Selumetinib During Oral Twice Daily Dose of Selumetinib
Time Frame: Day 8: 0, 0.5, 1, 1.5, 2, 4, 8, 12 hours post-dose
Pharmacokinetic parameter (tmax: time to reach the maximum plasma concentration) of Selumetinib during oral twice daily dose of Selumetinib
Secondary Outcomes
- Cmax of Docetaxel Following Intravenous Infusion of Docetaxel 60 mg/m2(Day 1: 0, 0.5, 1, 1.5, 2, 4, 8, 12 hours post-dose)
- AUC(0-12) of Docetaxel Following Intravenous Infusion of Docetaxel 60 mg/m2(Day 1: 0, 0.5, 1, 1.5, 2, 4, 8, 12 hours post-dose)
- Tmax of Docetaxel Following Intravenous Infusion of Docetaxel 60 mg/m2(Day 1: 0, 0.5, 1, 1.5, 2, 4, 8, 12 hours post-dose)